Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trialCatia Simoes, Pau Montesinos, Pilar Herrera et al.|Blood Advances|2021Cited by 25
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemiaCatia Simoes, Bruno Paiva, Carmen Chillón et al.|Blood Advances|2022Cited by 8
The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patientsSara Villar, Pau Montesinos, Beñat Ariceta et al.|Frontiers in Oncology|2022Cited by 7
Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemiaCatia Simoes, Patrik Fazio, Carmen González et al.|Blood Neoplasia|2024Cited by 2